Drug intelligence / Profile preview

TML-ORP-21

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Small Molecules
Administration: Injection

Overview

TML-ORP-21 is a preclinical-stage sedative-hypnotic agent being developed by Themis Medicare. It is designed as a ready-to-use (RTU) injection, utilizing a novel drug delivery system (NDDS) or new dosage form to improve ease of administration and potentially enhance the safety or stability profile compared to traditional formulations. As a sedative-hypnotic, it is intended for use in inducing or maintaining sedation or sleep, typically in clinical or surgical settings. The specific active pharmaceutical ingredient (API) represented by the 'ORP' code has not been publicly disclosed by the developer, but the project is part of Themis Medicare's specialized pipeline focusing on injectable NDDS products.

Other names: Themis Medicare Sedative-Hypnotic RTU Injection

Beyond the preview

Go deeper on TML-ORP-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-ORP-21.

Explore the full profile